Results 81 to 90 of about 18,669 (233)
Current State of Moderate Congenital Haemophilia A and the Need for Preventive Treatment
Haemophilia, EarlyView.ABSTRACT Introduction The severity of haemophilia A is classified by the degree of factor VIII (FVIII) deficiency, rather than by clinical manifestations. However, FVIII activity alone does not necessarily accurately reflect clinical severity such as bleeding tendency, and patients with mild‐to‐moderate haemophilia A can experience significant disease ...
Masahiro Takeyama +6 more
wiley +1 more source
The XX Factor in Hemophilia: Diagnostic, Therapeutic, and Research Gaps for Women and Girls
Haemophilia, EarlyView.ABSTRACT Introduction Hemophilia has traditionally been viewed as an X‐linked disorder affecting men and boys, with women and girls labeled as “carriers”, presumed to be clinically unaffected. This paradigm has contributed to under‐recognition, delayed diagnosis, and undertreatment of females with hemophilia‐associated genotypes despite an increasingly
Kelsey Uminski, Ellen Cusano
wiley +1 more source
Understanding the Experiences of Young People Living With Haemophilia—A UK Social Media Study
Haemophilia, EarlyView.ABSTRACT Introduction Haemophilia is a rare congenital bleeding disorder that presents significant physical and psychological challenges, especially for young people, with limited real‐world evidence about their experiences in the UK. Aim This study sought to understand the perspectives and challenges of young people living with haemophilia in the UK ...
Emma Gayton +6 more
wiley +1 more source
Haemophilia, EarlyView.ABSTRACT Introduction The accurate physical examination of musculoskeletal (MSK) health is an essential part of proactive best practice care of people with hemophilia and must be consistently monitored in clinic. In response to current MSK tool limitations, the Musculoskeletal Health Expert Working Group (MSKH EWG) of the International Prophylaxis ...
Lizabeth Teshler +16 more
wiley +1 more source
Correction to: Eftrenonacog Alfa: A Review in Haemophilia B. [PDF]
Drugs, 2023 Lamb YN, Hoy SM.
europepmc +1 more source
Haemophilia, EarlyView.ABSTRACT Introduction Over the past decade, hemophilia management has been transformed by modern prophylactic strategies, achieving dramatic reductions in annualized bleeding rates (ABR), often approaching zero. However, the conceptual evolution of hemophilia care toward multidimensional health assessment and comprehensive multidisciplinary management ...
Nicolas Giraud, Yesim Dargaud
wiley +1 more source
The Burden of Prior Authorizations in Bleeding Disorder Specialty Drugs
Haemophilia, EarlyView.ABSTRACT Introduction Prior authorizations (PAs) are widely used to control healthcare costs and ensure appropriate use of high‐cost therapies, but they often create undue administrative burdens. In haemophilia care, timely access to specialty medications is critical, yet Haemophilia Treatment Centres (HTCs) must frequently navigate payer‐driven PA ...
Lisa Littner +3 more
wiley +1 more source
Iranian Journal of Allergy, Asthma and Immunology, 2006 Many investigations have proved relations between ABO blood groups with some diseases and factor VIII and von willebrand level in plasma. In this study we investigated a relation between ABO blood groups and factor VIII and IX inhibitors in 102 patients ...
Hassan Mansouri Torghabeh +3 more
doaj
Haemophilia, EarlyView.ABSTRACT Introduction Understanding patients’ and caregivers’ experiences, values and needs is essential to implement patient‐centred care. However, specific insights into how young children with haemophilia and their caregivers experience the entire care trajectory, from diagnosis onwards, remain limited.
Caroline M. A. Mussert +11 more
wiley +1 more source